先天性肾上腺皮质增生症患儿的安替比林清除率及代谢物形成情况
Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.
作者信息
Teunissen M W, Bruining G J, De Jongh B M, Tenkate-Westerhof E W, Breimer D D
出版信息
Br J Clin Pharmacol. 1985 Dec;20(6):703-6. doi: 10.1111/j.1365-2125.1985.tb05134.x.
Abstract
Antipyrine salivary clearance and half-life and the rate of formation of three principal metabolites of antipyrine (4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine) were assessed in nine children with congenital adrenal hyperplasia, six of whom were salt-losers and three of whom were non-salt-losers. No differences were found in comparison with data obtained in normal children.
摘要
对9名先天性肾上腺皮质增生症患儿的安替比林唾液清除率、半衰期以及安替比林三种主要代谢产物（4-羟基安替比林、3-羟甲基安替比林和去甲安替比林）的生成速率进行了评估，其中6名是失盐型，3名是非失盐型。与正常儿童获得的数据相比，未发现差异。
相似文献
1
Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.先天性肾上腺皮质增生症患儿的安替比林清除率及代谢物形成情况
Br J Clin Pharmacol. 1985 Dec;20(6):703-6. doi: 10.1111/j.1365-2125.1985.tb05134.x.
2
Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.安替比林作为人类氧化药物代谢的探针：催化4-羟基安替比林、3-羟甲基安替比林和去甲安替比林形成的细胞色素P450酶的鉴定。
Clin Pharmacol Ther. 1996 Jun;59(6):613-23. doi: 10.1016/S0009-9236(96)90001-6.
3
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.大鼠中安替比林不同代谢途径的研究：苯巴比妥和3-甲基胆蒽处理的影响
Xenobiotica. 1979 Nov;9(11):695-702. doi: 10.3109/00498257909042337.
4
Antipyrine clearance in congenital adrenal hyperplasia.先天性肾上腺增生症中的安替比林清除率
Clin Endocrinol (Oxf). 1986 Sep;25(3):233-9. doi: 10.1111/j.1365-2265.1986.tb01687.x.
5
Differential effects of enzyme induction on antipyrine metabolite formation.酶诱导作用对安替比林代谢物形成的不同影响。
Br J Clin Pharmacol. 1982 Mar;13(3):379-86. doi: 10.1111/j.1365-2125.1982.tb01389.x.
6
Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.安替比林清除率及代谢物形成：肝脏体积与吸烟的影响
Eur J Clin Invest. 1986 Aug;16(4):321-7. doi: 10.1111/j.1365-2362.1986.tb01349.x.
7
Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.利福平、苯巴比妥和西咪替丁对异喹胍快代谢型和慢代谢型中混合功能单加氧酶的影响。
Int J Clin Pharmacol Ther Toxicol. 1989 Dec;27(12):593-8.
8
Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.轻度甲状腺功能障碍对人体安替比林清除率及代谢物形成的影响。
Eur J Clin Pharmacol. 1984;27(1):99-103.
9
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.去甲丙咪嗪羟基化的基因控制缺陷对安替比林代谢物形成的影响。
Pharmacology. 1981;22(6):349-58. doi: 10.1159/000137515.
10
Differential induction of antipyrine metabolism by rifampicin.利福平对安替比林代谢的差异诱导作用。
Eur J Clin Pharmacol. 1981;21(2):155-60. doi: 10.1007/BF00637517.
本文引用的文献
1
Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.营养不良急性期及恢复后儿童中安替比林代谢物的形成
Br J Clin Pharmacol. 1980 Oct;10(4):363-8. doi: 10.1111/j.1365-2125.1980.tb01772.x.
2
Differential induction of antipyrine metabolism by rifampicin.利福平对安替比林代谢的差异诱导作用。
Eur J Clin Pharmacol. 1981;21(2):155-60. doi: 10.1007/BF00637517.
3
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.去甲丙咪嗪羟基化的基因控制缺陷对安替比林代谢物形成的影响。
Pharmacology. 1981;22(6):349-58. doi: 10.1159/000137515.
4
Effects of growth hormone on antipyrine kinetics in children.
Clin Pharmacol Ther. 1981 Jul;30(1):127-32. doi: 10.1038/clpt.1981.137.
5
Differential effects of enzyme induction on antipyrine metabolite formation.酶诱导作用对安替比林代谢物形成的不同影响。
Br J Clin Pharmacol. 1982 Mar;13(3):379-86. doi: 10.1111/j.1365-2125.1982.tb01389.x.
6
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
7
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.安替比林代谢产物形成变异的单基因控制。肝脏药物氧化的新多态性。
J Clin Invest. 1983 Jun;71(6):1698-709. doi: 10.1172/jci110924.
8
9
Interindividual variations in drug disposition. Clinical implications and methods of investigation.药物处置的个体间差异。临床意义及研究方法。
Clin Pharmacokinet. 1983 Sep-Oct;8(5):371-7. doi: 10.2165/00003088-198308050-00001.
10
Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.酒精性肝硬化患者的安替比林清除率及代谢产物形成情况
Br J Clin Pharmacol. 1984 Nov;18(5):707-15. doi: 10.1111/j.1365-2125.1984.tb02533.x.
Zotero 插件